

## Boston Scientific Announces Schedule of Presentations at EuroPCR 2018

MARLBOROUGH, Mass., May 16, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of key presentations, including two late-breaking clinical trials, that will be featured at the annual EuroPCR Scientific Program, in Paris, on May 22-25.

During the late-breaking sessions on Wednesday, May 23, data from the RESPOND trial will provide two-year, 'real world' outcomes in patients treated with the LOTUS™ Transcatheter Aortic Valve System\* as well as one-year results with the Agent™ Paclitaxel-Coated PTCA Balloon\*\* from a multicenter study of two drug-coated balloons in patients with arterial in-stent restenosis.

Other presentations of interest include two sub-analyses from the REPRISE III randomized trial, also featuring the LOTUS Valve: multivariate predictors of early and late stroke after implantation and gender-related differences in clinical presentation and outcomes after TAVI. Data regarding the matched comparison of anticoagulation vs. antiplatelet therapy after LAA closure with the WATCHMAN™ Left Atrial Appendage Device will also be presented.

"We feel that this year's EuroPCR program will serve as a backdrop for engaging dialogue around data milestones that demonstrate the strength of our cardiovascular portfolio," said Professor Ian Meredith, M.D., executive vice president and global chief medical officer, Boston Scientific. "Additionally, we have been anticipating the outcomes from multiple studies being presented around our SYNERGY™ Bioabsorbable Polymer Stent, including further insight into assessing outcomes associated with patients presenting with complex disease states, high bleeding risk and shorter dual anti-platelet regimens."

### **SCHEDULE OF PRESENTATIONS OF INTEREST** (listed chronologically)

#### **Tuesday, May 22**

- **The LOTUS Valve System:** Insights from the randomized REPRISE III trial - Multivariate predictors of early and late stroke after TAVI implantation. Prof. Axel Linke will present at 12:26 in Room342B, Level 3.
- **The LOTUS Valve System:** REPRISE III gender sub-analysis: Sex-related differences in clinical presentation and outcome after TAVI for severe aortic stenosis. Dr. Mayra Guerrero will present insights from the randomized REPRISE III trial at 13:30 in the Posters Lab, Level 1.

#### **Wednesday, May 23**

- **The LOTUS Valve System:** RESPOND: 2 years clinical outcomes in patients treated with a repositionable and fully retrievable aortic valve in routine clinical practice. Dr. David Hildick-Smith will present the results at 09:36 in Room Maillot, Level 2.
- **Agent Drug-Coated Balloon:** AGENT ISR: One-year outcomes from a randomized multi-centre study of two DEB for the treatment of coronary in-stent restenosis. Prof. Dr. Holger Nef will present the clinical outcomes at 14:45 in Room Maillot, Level 2.

#### **Thursday, May 24**

- **The WATCHMAN Left Atrial Appendage Device:** Propensity-matched comparison of anticoagulation vs. antiplatelet therapy after LAAC with Watchman. Prof. Lars Søndergaard will present at 14:45 in Room 252B, Level 2.

All events are listed in Central European Summer Time (CEST) and take place at the Palais des Congrès. For additional details about Boston Scientific data presentations and sponsored symposia, go to [www.bostonscientific.eu/euroPCR-2018](http://www.bostonscientific.eu/euroPCR-2018) or visit the Boston Scientific booth located on Level 1, Hall Passy F21. For more information about Boston Scientific at EuroPCR, please follow [@BSC\\_EU\\_Heart](https://twitter.com/BSC_EU_Heart).

\*The LOTUS Valve system is currently not available for use or sale.

\*\*In the U.S., the Agent™ Paclitaxel-Coated balloon catheter is investigational and not available for sale.

#### **About Boston Scientific**

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit [www.bostonscientific.com](http://www.bostonscientific.com) and connect on [Twitter](https://twitter.com/BSC_EU_Heart), [LinkedIn](https://www.linkedin.com/company/boston-scientific) and [Facebook](https://www.facebook.com/boston-scientific).

**CONTACTS:**

Timette Nevala  
U.S. Media  
(763) 494-1284 (office)  
[Timette.Nevala@bsci.com](mailto:Timette.Nevala@bsci.com)

Rainer Puster  
European Media  
+49 (0) 1754347057  
[Rainer.Puster@bsci.com](mailto:Rainer.Puster@bsci.com)

Susie Lisa, CFA  
Investor Relations  
(508) 683-5565 (office)  
[BSXInvestorRelations@bsci.com](mailto:BSXInvestorRelations@bsci.com)

SOURCE Boston Scientific Corporation

---

<https://stage.mediaroom.com/bostonscientific/2018-05-16-Boston-Scientific-Announces-Schedule-of-Presentations-at-EuroPCR-2018>